{"id":2527,"date":"2018-01-25T18:01:38","date_gmt":"2018-01-25T12:31:38","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2527"},"modified":"2023-04-04T10:44:44","modified_gmt":"2023-04-04T05:14:44","slug":"business-cocktail-pharma-news","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-pharma-news","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Pharma startup Bonti has recently grabbed a funding of USD 15 million<\/strong><\/p>\n<p style=\"text-align: justify;\">Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C, The Company is focused on developing a new botulinum neurotoxin for both therapeutic and cosmetic uses. Funding will help in the development of company\u2019s lead drug, EB-001 and in other market research activities.<\/p>\n<p style=\"text-align: justify;\"><strong>NIH to boost up the gene editing development process by putting USD 190 million<\/strong><\/p>\n<p style=\"text-align: justify;\">Recently, the Gene-editing techniques such as CRISPR-Cas9 has grabbed a lot of attention after showing some promising results and are already transforming research. But there is still a long way ahead before this technique could become worthy as human therapeutics. The National Institutes of Health (NIH) has decided to boost the process by putting USD 190 million into a program to develop gene editing therapy.<\/p>\n<p style=\"text-align: justify;\"><strong>Skyhawk Therapeutics grabbed a funding of USD 8 million RNA targeted therapy<\/strong><\/p>\n<p style=\"text-align: justify;\">Pharmaceutical startup Skyhawk Therapeutics grabbed a funding of&nbsp;USD 8 million to move small molecules that targets and correct the RNA expression into the clinic phases. The startup is going ahead with the same combination of executives and investors that have powered another pharma company Dragonfly Therapeutics to a deal with Celgene for the natural killer cell.<\/p>\n<p style=\"text-align: justify;\"><strong>Tmunity Therapeutics successfully scored USD 100 million for advance T-cell immunotherapies<\/strong><\/p>\n<p style=\"text-align: justify;\">In the quest to bring better and safer T-cell Immunotherapies for both solid tumors and blood cancers, Tmunity Therapeutics and has successfully grabbed a funding of USD 100 million in series A funding. Ping An Ventures, the Parker Institute for Cancer Immunotherapy, Gilead, the University of Pennsylvania and Lilly Asia Ventures, backed the funding series.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharma startup Bonti has recently grabbed a funding of USD 15 million Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C, The Company is focused on developing a new botulinum neurotoxin for both therapeutic and cosmetic uses. Funding will help in the development of company\u2019s [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[70,1343,1344,155,1342,647,204,1349,657,349,1345,1346,1230,1261,639,1183,1348,1347,1351,1350],"industry":[17225],"therapeutic_areas":[17235,17228,17278],"class_list":["post-2527","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-allergan","tag-bonti","tag-botulinum-neurotoxin","tag-celgene","tag-consulting","tag-crispr","tag-delveinsight","tag-dragonfly-therapeutics","tag-gene-editing","tag-latest-pharma-news","tag-national-institutes-of-health","tag-nih","tag-pharma-consultancy","tag-pharma-consulting","tag-pharma-news","tag-pharmaceutical-news","tag-rna-targeted-therapy","tag-skyhawk-therapeutics","tag-t-cell-immunotherapies","tag-tmunity-therapeutics","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Business Cocktail- Latest Pharmaceutical Industry News<\/title>\n<meta name=\"description\" content=\"Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C for developing lead drug, EB-001\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-pharma-news\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Business Cocktail- Latest Pharmaceutical Industry News\" \/>\n<meta property=\"og:description\" content=\"Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C for developing lead drug, EB-001\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-pharma-news\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-25T12:31:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T05:14:44+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Business Cocktail- Latest Pharmaceutical Industry News","description":"Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C for developing lead drug, EB-001","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-pharma-news","og_locale":"en_US","og_type":"article","og_title":"Business Cocktail- Latest Pharmaceutical Industry News","og_description":"Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C for developing lead drug, EB-001","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-pharma-news","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-01-25T12:31:38+00:00","article_modified_time":"2023-04-04T05:14:44+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-pharma-news","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-pharma-news","name":"Business Cocktail- Latest Pharmaceutical Industry News","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2018-01-25T12:31:38+00:00","dateModified":"2023-04-04T05:14:44+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Managed by Ex-Allergan executives biotech startup Bonti has recently bagged a funding of USD 15.5 million in series C for developing lead drug, EB-001","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-pharma-news"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bonti<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">botulinum neurotoxin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dragonfly Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene editing<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">National Institutes of Health<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NIH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">RNA targeted therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Skyhawk Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">T-cell immunotherapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tmunity Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Bonti<\/span>","<span class=\"advgb-post-tax-term\">botulinum neurotoxin<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">consulting<\/span>","<span class=\"advgb-post-tax-term\">CRISPR<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Dragonfly Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Gene editing<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">National Institutes of Health<\/span>","<span class=\"advgb-post-tax-term\">NIH<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical news<\/span>","<span class=\"advgb-post-tax-term\">RNA targeted therapy<\/span>","<span class=\"advgb-post-tax-term\">Skyhawk Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">T-cell immunotherapies<\/span>","<span class=\"advgb-post-tax-term\">Tmunity Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 25, 2018","modified":"Updated on Apr 4, 2023"},"absolute_dates_time":{"created":"Posted on Jan 25, 2018 6:01 pm","modified":"Updated on Apr 4, 2023 10:44 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2527"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2527\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2527"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2527"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}